慢性C 型肝炎是引起肝病的重要原因。在台灣以長效干擾素(pegylated interferon) 合併雷 巴威林(ribavirin) 的治療雖有健保給付，但有其禁忌症及副作用，且療效仍未令人十分滿意。 近幾年，直接作用抗病毒藥物(direct-acting antiviral agent, DAA) 的研發不斷進展，全口服免 用干擾素的治療藥物已在歐、美、日等國家上市，並顯示其成效良好，但其價格甚高，目前 在台灣無健保給付且需專案申請進口。熟悉瞭解此些藥物，並在病患經濟能力許可下，新藥 可提供臨床醫師與病患對抗C 型肝炎一項新的選擇。

Chronic hepatitis C is an important cause of liver disease. Although treatment with pegylated interferon and ribavirin is covered by national health insurance in Taiwan, its contraindications, side effects and limited results make this treatment still unsatisfactory. In recent years, researches of interferon-free treatment with all-oral directacting antiviral agents (DAA) for chronic hepatitis C progressed rapidly, revealed good treatment effects and these agents are approved in Europe, United states and Japan. These treatments are expensive, have not been covered by national health insurance, and have not been approved in Taiwan yet. However, after filing special applications, physicians still could consider all-oral DAA to treat patients who indeed require and could afford these new agents in Taiwan.